Mineralys Therapeutics, Inc.
MLYSNASDAQHealthcare● Active
$22.89
$-0.81(-3.40%)
Market Cap$1.5B
P/E Ratio—
52W High$47.65
52W Low$12.59
Mineralys Therapeutics, Inc. (MLYS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MLYS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.47
Est. -$0.51 · +7.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
MLYS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.54 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.51 | -$0.47 | +7.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.52 | -$0.40 | +22.5% | — | — | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.66 | -$0.52 | +21.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.78 | -$0.66 | +15.4% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$1.02 | -$0.79 | +22.6% | — | — | — |
| ▲ Q1 FY2025 | Feb 12, 2025 | -$1.00 | -$0.98 | +2.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 11, 2024 | -$0.83 | -$1.13 | -36.1% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.54
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.47
EPS Est.
-$0.51
EPS Surpr.
+7.8%
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.40
EPS Est.
-$0.52
EPS Surpr.
+22.5%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$0.66
EPS Surpr.
+21.2%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.66
EPS Est.
-$0.78
EPS Surpr.
+15.4%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.79
EPS Est.
-$1.02
EPS Surpr.
+22.6%
Revenue
—
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
-$0.98
EPS Est.
-$1.00
EPS Surpr.
+2.0%
Revenue
—
Q4 FY2024
Nov 11, 2024Miss
EPS Actual
-$1.13
EPS Est.
-$0.83
EPS Surpr.
-36.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.34 | $-0.34 | $-0.34 | 2 |
| Q3 FY2028 | $-0.39 | $-0.39 | $-0.39 | 2 |
| Q2 FY2028 | $-0.44 | $-0.44 | $-0.44 | 2 |
| Q1 FY2028 | $-0.49 | $-0.49 | $-0.49 | 2 |
| Q4 FY2027 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q3 FY2027 | $-0.62 | $-0.62 | $-0.62 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +7.8% | $29.28 | $30.12 | +2.87% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +22.5% | $27.97 | $26.99 | -3.50% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +21.2% | $38.02 | $44.50 | +17.04% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +15.4% | $13.19 | $13.51 | +2.43% |
| ▲ Q2 FY2025 | May 12, 2025 | +22.6% | $14.65 | $15.01 | +2.46% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +2.0% | $9.66 | $10.63 | +10.04% |
| ▼ Q4 FY2024 | Nov 11, 2024 | -36.1% | $14.04 | $14.92 | +6.27% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -13.7% | $11.34 | $11.83 | +4.32% |
Q2 FY2026+2.87%
Report Date
May 6, 2026
EPS Beat/Miss
+7.8%
Price Before
$29.28
Price After
$30.12
Q1 FY2026-3.50%
Report Date
Mar 12, 2026
EPS Beat/Miss
+22.5%
Price Before
$27.97
Price After
$26.99
Q4 FY2025+17.04%
Report Date
Nov 10, 2025
EPS Beat/Miss
+21.2%
Price Before
$38.02
Price After
$44.50
Q3 FY2025+2.43%
Report Date
Aug 12, 2025
EPS Beat/Miss
+15.4%
Price Before
$13.19
Price After
$13.51
Q2 FY2025+2.46%
Report Date
May 12, 2025
EPS Beat/Miss
+22.6%
Price Before
$14.65
Price After
$15.01
Q1 FY2025+10.04%
Report Date
Feb 12, 2025
EPS Beat/Miss
+2.0%
Price Before
$9.66
Price After
$10.63
Q4 FY2024+6.27%
Report Date
Nov 11, 2024
EPS Beat/Miss
-36.1%
Price Before
$14.04
Price After
$14.92
Q3 FY2024+4.32%
Report Date
Aug 13, 2024
EPS Beat/Miss
-13.7%
Price Before
$11.34
Price After
$11.83
Avg Beat Reaction+5.22%
Avg Miss Reaction+5.29%
Beat Rate6 / 8 quarters
Largest Move+17.04% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MLYS ends December
Mineralys Therapeutics, Inc. (MLYS) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.47 — beating the analyst consensus of $-0.51 by +7.8%. MLYS has beaten EPS estimates for 6 consecutive quarters. The next MLYS earnings date is expected around September 1, 2026.
Each quarter, investors track MLYS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MLYS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MLYS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MLYS earnings · 5 questionsMineralys Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. MLYS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MLYS historically reports after market close (AMC).
MLYS earnings datewhen is MLYS earningsMLYS next earnings datewhen does MLYS report earningsMLYS earnings calendar
▸ Source: FMP · Mineralys Therapeutics, Inc. SEC filings · US GAAP · Mineralys Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026